Autolus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUTL and other ETFs, options, and stocks.

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. 

CEO
Christian Martin Itin
CEOChristian Martin Itin
Employees
647
Employees647
Headquarters
London, Greater London
HeadquartersLondon, Greater London
Founded
2018
Founded2018
Employees
647
Employees647

AUTL Key Statistics

Market cap
368.61M
Market cap368.61M
Price-Earnings ratio
-1.62
Price-Earnings ratio-1.62
Dividend yield
Dividend yield
Average volume
1.73M
Average volume1.73M
High today
$1.41
High today$1.41
Low today
$1.36
Low today$1.36
Open price
$1.38
Open price$1.38
Volume
1.09M
Volume1.09M
52 Week high
$2.70
52 Week high$2.70
52 Week low
$1.11
52 Week low$1.11

AUTL News

TipRanks 7d
Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement

Claim 50% Off TipRanks Premium Autolus Therapeutics ( (AUTL) ) has provided an update. On January 21, 2026, Autolus Limited, a subsidiary of Autolus Therapeut...

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.